France will take a stake in Sanofi’s (SNY) Opella through the Public Investment Bank, or BPI, finance minister Antoine Armand said on Sunday, confirming an information from Le Figaro newspaper that U.S. private equity firm Clayton Dubilier & Rice, or CD&R, is to take a 51% stake in the company that makes of one of France’s most-sold painkillers, Doliprane, according to Reuters. The plan for Public Investment Bank to take a 1% stake in Opella, for about EUR 150M, or $162.98M, came through a tri-party agreement between Sanofi, the French state and CD&R and was approved by Sanofi’s board on Sunday, the newspaper said.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi aims to sign consumer health sales pact with CD&R shortly, Bloomberg says
- Uber said to consider Expedia bid, CSX posts Q3 miss: Morning Buzz
- Sanofi in talks with French government over Opella sale, WSJ says
- FDA updates U.S. label for Sanofi’s FLUBLOK
- Exscientia advances two additional discovery programs with Sanofi
